Global Biosimilars of Rituximab Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Publisher Name :
Date: 15-Dec-2022
No. of pages: 117
Inquire Before Buying

Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.

Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.

The USA market for Biosimilars of Rituximab is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The China market for Biosimilars of Rituximab is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The Europe market for Biosimilars of Rituximab is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The global key manufacturers of Biosimilars of Rituximab include Amgen, AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddy's Laboratories, Teva, Hetero Group and Innovent Biologics, etc. In 2021, the global top five players had a share approximately % in terms of revenue.

Report Scope

This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Biosimilars of Rituximab manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Biosimilars of Rituximab market. Further, it explains the major drivers and regional dynamics of the global Biosimilars of Rituximab market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

- Amgen

- AryoGen Pharmed

- Biocad

- Cadila Pharmaceuticals

- Celltrion

- Dr Reddy's Laboratories

- Teva

- Hetero Group

- Innovent Biologics

- Intas Biopharmaceuticals

- Mylan

- Probiomed

- TRPharma

- Zenotech Laboratories

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.

Biosimilars of Rituximab Segment by Type

- 500mg

- 100mg

- Other

Biosimilars of Rituximab Segment by Application

- Hospital Pharmacy

- Retail Pharmacy

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - China Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Biosimilars of Rituximab market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Biosimilars of Rituximab, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Biosimilars of Rituximab, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Biosimilars of Rituximab, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilars of Rituximab sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Biosimilars of Rituximab market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Biosimilars of Rituximab sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Amgen, AryoGen Pharmed, Biocad, Cadila Pharmaceuticals, Celltrion, Dr Reddy's Laboratories, Teva, Hetero Group and Innovent Biologics, etc.

Global Biosimilars of Rituximab Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Market Segment by Type
1.2.1 Global Biosimilars of Rituximab Market Size Growth Rate by Type (2017 VS 2021 VS 2028)
1.2.2 500mg
1.2.3 100mg
1.2.4 Other
1.3 Market Segment by Application
1.3.1 Global Biosimilars of Rituximab Market Share by Application (2017 VS 2021 VS 2028)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Biosimilars of Rituximab Market Size (2017-2028)
2.1.1 Global Biosimilars of Rituximab Revenue (2017-2028)
2.1.2 Global Biosimilars of Rituximab Sales (2017-2028)
2.2 Global Biosimilars of Rituximab Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.2.1 Global Biosimilars of Rituximab Sales by Regions (2017-2022)
2.2.2 Global Biosimilars of Rituximab Revenue by Regions (2017-2022)
2.3 Global Biosimilars of Rituximab Market Size Forecast by Region
2.3.1 Global Biosimilars of Rituximab Sales Forecast by Region (2023-2028)
2.3.2 Global Biosimilars of Rituximab Revenue Forecast by Region (2023-2028)
2.4 Global Top Biosimilars of Rituximab Regions (Countries) Ranking by Market Size
2.5 Biosimilars of Rituximab Market Dynamics
2.5.1 Biosimilars of Rituximab Market Trends
2.5.2 Biosimilars of Rituximab Market Drivers
2.5.3 Biosimilars of Rituximab Market Challenges
2.5.4 Biosimilars of Rituximab Market Restraints
3 Competitive Landscape by Manufacturers
3.1 Global Top Biosimilars of Rituximab Manufacturers by Sales (2017-2022)
3.1.1 Global Biosimilars of Rituximab Sales by Manufacturers (2017-2022)
3.1.2 Global Biosimilars of Rituximab Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global 5 and 10 Largest Manufacturers by Biosimilars of Rituximab Sales in 2021
3.2 Global Top Manufacturers Biosimilars of Rituximab by Revenue
3.2.1 Global Biosimilars of Rituximab Revenue by Manufacturers (2017-2022)
3.2.2 Top Biosimilars of Rituximab Manufacturers Covered: Ranking by Revenue
3.2.3 Global Biosimilars of Rituximab Revenue Share by Manufacturers (2017-2022)
3.2.4 Global Biosimilars of Rituximab Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilars of Rituximab as of 2021)
3.4 Global Biosimilars of Rituximab Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Biosimilars of Rituximab Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Biosimilars of Rituximab Market
3.7 Key Manufacturers Biosimilars of Rituximab Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Biosimilars of Rituximab Market Size by Type
4.1 Global Biosimilars of Rituximab Historic Market Review by Type (2017-2022)
4.1.1 Global Biosimilars of Rituximab Sales Market Share by Type (2017-2022)
4.1.2 Global Biosimilars of Rituximab Revenue Market Share by Type (2017-2022)
4.1.3 Biosimilars of Rituximab Price by Type (2017-2022)
4.2 Global Biosimilars of Rituximab Market Estimates and Forecasts by Type (2023-2028)
4.2.1 Global Biosimilars of Rituximab Sales Forecast by Type (2023-2028)
4.2.2 Global Biosimilars of Rituximab Revenue Forecast by Type (2023-2028)
4.2.3 Biosimilars of Rituximab Price Forecast by Type (2023-2028)
5 Global Biosimilars of Rituximab Market Size by Application
5.1 Global Biosimilars of Rituximab Historic Market Review by Application (2017-2022)
5.1.1 Global Biosimilars of Rituximab Sales Market Share by Application (2017-2022)
5.1.2 Global Biosimilars of Rituximab Revenue Market Share by Application (2017-2022)
5.1.3 Biosimilars of Rituximab Price by Application (2017-2022)
5.2 Global Biosimilars of Rituximab Market Estimates and Forecasts by Application (2023-2028)
5.2.1 Global Biosimilars of Rituximab Sales Forecast by Application (2023-2028)
5.2.2 Global Biosimilars of Rituximab Revenue Forecast by Application (2023-2028)
5.2.3 Biosimilars of Rituximab Price Forecast by Application (2023-2028)
6 North America
6.1 North America Biosimilars of Rituximab Sales Breakdown by Company
6.1.1 North America Biosimilars of Rituximab Sales by Company (2017-2022)
6.1.2 North America Biosimilars of Rituximab Revenue by Company (2017-2022)
6.2 North America Biosimilars of Rituximab Market Size by Type
6.2.1 North America Biosimilars of Rituximab Sales by Type (2017-2028)
6.2.2 North America Biosimilars of Rituximab Revenue by Type (2017-2028)
6.3 North America Biosimilars of Rituximab Market Size by Application
6.3.1 North America Biosimilars of Rituximab Sales by Application (2017-2028)
6.3.2 North America Biosimilars of Rituximab Revenue by Application (2017-2028)
6.4 North America Biosimilars of Rituximab Market Size by Country
6.4.1 North America Biosimilars of Rituximab Sales by Country (2017-2028)
6.4.2 North America Biosimilars of Rituximab Revenue by Country (2017-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Biosimilars of Rituximab Sales Breakdown by Company
7.1.1 Europe Biosimilars of Rituximab Sales by Company (2017-2022)
7.1.2 Europe Biosimilars of Rituximab Revenue by Company (2017-2022)
7.2 Europe Biosimilars of Rituximab Market Size by Type
7.2.1 Europe Biosimilars of Rituximab Sales by Type (2017-2028)
7.2.2 Europe Biosimilars of Rituximab Revenue by Type (2017-2028)
7.3 Europe Biosimilars of Rituximab Market Size by Application
7.3.1 Europe Biosimilars of Rituximab Sales by Application (2017-2028)
7.3.2 Europe Biosimilars of Rituximab Revenue by Application (2017-2028)
7.4 Europe Biosimilars of Rituximab Market Size by Country
7.4.1 Europe Biosimilars of Rituximab Sales by Country (2017-2028)
7.4.2 Europe Biosimilars of Rituximab Revenue by Country (2017-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Biosimilars of Rituximab Sales Breakdown by Company
8.1.1 Asia Pacific Biosimilars of Rituximab Sales by Company (2017-2022)
8.1.2 Asia Pacific Biosimilars of Rituximab Revenue by Company (2017-2022)
8.2 Asia Pacific Biosimilars of Rituximab Market Size by Type
8.2.1 Asia Pacific Biosimilars of Rituximab Sales by Type (2017-2028)
8.2.2 Asia Pacific Biosimilars of Rituximab Revenue by Type (2017-2028)
8.3 Asia Pacific Biosimilars of Rituximab Market Size by Application
8.3.1 Asia Pacific Biosimilars of Rituximab Sales by Application (2017-2028)
8.3.2 Asia Pacific Biosimilars of Rituximab Revenue by Application (2017-2028)
8.4 Asia Pacific Biosimilars of Rituximab Market Size by Region
8.4.1 Asia Pacific Biosimilars of Rituximab Sales by Region
8.4.2 Asia Pacific Biosimilars of Rituximab Revenue by Region
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 China Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
9 Latin America
9.1 Latin America Biosimilars of Rituximab Sales Breakdown by Company
9.1.1 Latin America Biosimilars of Rituximab Sales by Company (2017-2022)
9.1.2 Latin America Biosimilars of Rituximab Revenue by Company (2017-2022)
9.2 Latin America Biosimilars of Rituximab Market Size by Type
9.2.1 Latin America Biosimilars of Rituximab Sales by Type (2017-2028)
9.2.2 Latin America Biosimilars of Rituximab Revenue by Type (2017-2028)
9.3 Latin America Biosimilars of Rituximab Market Size by Application
9.3.1 Latin America Biosimilars of Rituximab Sales by Application (2017-2028)
9.3.2 Latin America Biosimilars of Rituximab Revenue by Application (2017-2028)
9.4 Latin America Biosimilars of Rituximab Market Size by Country
9.4.1 Latin America Biosimilars of Rituximab Sales by Country (2017-2028)
9.4.2 Latin America Biosimilars of Rituximab Revenue by Country (2017-2028)
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Biosimilars of Rituximab Sales Breakdown by Company
10.1.1 Middle East and Africa Biosimilars of Rituximab Sales by Company (2017-2022)
10.1.2 Middle East and Africa Biosimilars of Rituximab Revenue by Company (2017-2022)
10.2 Middle East and Africa Biosimilars of Rituximab Market Size by Type
10.2.1 Middle East and Africa Biosimilars of Rituximab Sales by Type (2017-2028)
10.2.2 Middle East and Africa Biosimilars of Rituximab Revenue by Type (2017-2028)
10.3 Middle East and Africa Biosimilars of Rituximab Market Size by Application
10.3.1 Middle East and Africa Biosimilars of Rituximab Sales by Application (2017-2028)
10.3.2 Middle East and Africa Biosimilars of Rituximab Revenue by Application (2017-2028)
10.4 Middle East and Africa Biosimilars of Rituximab Market Size by Country
10.4.1 Middle East and Africa Biosimilars of Rituximab Sales by Country (2017-2028)
10.4.2 Middle East and Africa Biosimilars of Rituximab Revenue by Country (2017-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Overview
11.1.3 Amgen Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.1.4 Amgen Biosimilars of Rituximab Products and Services
11.1.5 Amgen Biosimilars of Rituximab SWOT Analysis
11.1.6 Amgen Recent Developments
11.2 AryoGen Pharmed
11.2.1 AryoGen Pharmed Corporation Information
11.2.2 AryoGen Pharmed Overview
11.2.3 AryoGen Pharmed Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.2.4 AryoGen Pharmed Biosimilars of Rituximab Products and Services
11.2.5 AryoGen Pharmed Biosimilars of Rituximab SWOT Analysis
11.2.6 AryoGen Pharmed Recent Developments
11.3 Biocad
11.3.1 Biocad Corporation Information
11.3.2 Biocad Overview
11.3.3 Biocad Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.3.4 Biocad Biosimilars of Rituximab Products and Services
11.3.5 Biocad Biosimilars of Rituximab SWOT Analysis
11.3.6 Biocad Recent Developments
11.4 Cadila Pharmaceuticals
11.4.1 Cadila Pharmaceuticals Corporation Information
11.4.2 Cadila Pharmaceuticals Overview
11.4.3 Cadila Pharmaceuticals Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.4.4 Cadila Pharmaceuticals Biosimilars of Rituximab Products and Services
11.4.5 Cadila Pharmaceuticals Biosimilars of Rituximab SWOT Analysis
11.4.6 Cadila Pharmaceuticals Recent Developments
11.5 Celltrion
11.5.1 Celltrion Corporation Information
11.5.2 Celltrion Overview
11.5.3 Celltrion Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.5.4 Celltrion Biosimilars of Rituximab Products and Services
11.5.5 Celltrion Biosimilars of Rituximab SWOT Analysis
11.5.6 Celltrion Recent Developments
11.6 Dr Reddy's Laboratories
11.6.1 Dr Reddy's Laboratories Corporation Information
11.6.2 Dr Reddy's Laboratories Overview
11.6.3 Dr Reddy's Laboratories Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.6.4 Dr Reddy's Laboratories Biosimilars of Rituximab Products and Services
11.6.5 Dr Reddy's Laboratories Biosimilars of Rituximab SWOT Analysis
11.6.6 Dr Reddy's Laboratories Recent Developments
11.7 Teva
11.7.1 Teva Corporation Information
11.7.2 Teva Overview
11.7.3 Teva Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.7.4 Teva Biosimilars of Rituximab Products and Services
11.7.5 Teva Biosimilars of Rituximab SWOT Analysis
11.7.6 Teva Recent Developments
11.8 Hetero Group
11.8.1 Hetero Group Corporation Information
11.8.2 Hetero Group Overview
11.8.3 Hetero Group Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.8.4 Hetero Group Biosimilars of Rituximab Products and Services
11.8.5 Hetero Group Biosimilars of Rituximab SWOT Analysis
11.8.6 Hetero Group Recent Developments
11.9 Innovent Biologics
11.9.1 Innovent Biologics Corporation Information
11.9.2 Innovent Biologics Overview
11.9.3 Innovent Biologics Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.9.4 Innovent Biologics Biosimilars of Rituximab Products and Services
11.9.5 Innovent Biologics Biosimilars of Rituximab SWOT Analysis
11.9.6 Innovent Biologics Recent Developments
11.10 Intas Biopharmaceuticals
11.10.1 Intas Biopharmaceuticals Corporation Information
11.10.2 Intas Biopharmaceuticals Overview
11.10.3 Intas Biopharmaceuticals Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.10.4 Intas Biopharmaceuticals Biosimilars of Rituximab Products and Services
11.10.5 Intas Biopharmaceuticals Biosimilars of Rituximab SWOT Analysis
11.10.6 Intas Biopharmaceuticals Recent Developments
11.11 Mylan
11.11.1 Mylan Corporation Information
11.11.2 Mylan Overview
11.11.3 Mylan Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.11.4 Mylan Biosimilars of Rituximab Products and Services
11.11.5 Mylan Recent Developments
11.12 Probiomed
11.12.1 Probiomed Corporation Information
11.12.2 Probiomed Overview
11.12.3 Probiomed Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.12.4 Probiomed Biosimilars of Rituximab Products and Services
11.12.5 Probiomed Recent Developments
11.13 TRPharma
11.13.1 TRPharma Corporation Information
11.13.2 TRPharma Overview
11.13.3 TRPharma Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.13.4 TRPharma Biosimilars of Rituximab Products and Services
11.13.5 TRPharma Recent Developments
11.14 Zenotech Laboratories
11.14.1 Zenotech Laboratories Corporation Information
11.14.2 Zenotech Laboratories Overview
11.14.3 Zenotech Laboratories Biosimilars of Rituximab Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2017-2022)
11.14.4 Zenotech Laboratories Biosimilars of Rituximab Products and Services
11.14.5 Zenotech Laboratories Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Biosimilars of Rituximab Value Chain Analysis
12.2 Biosimilars of Rituximab Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilars of Rituximab Production Mode & Process
12.4 Biosimilars of Rituximab Sales and Marketing
12.4.1 Biosimilars of Rituximab Sales Channels
12.4.2 Biosimilars of Rituximab Distributors
12.5 Biosimilars of Rituximab Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Biosimilars of Rituximab Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of 500mg
Table 3. Major Manufacturers of 100mg
Table 4. Major Manufacturers of Other
Table 5. Global Biosimilars of Rituximab Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Biosimilars of Rituximab Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 7. Global Biosimilars of Rituximab Sales by Region (2017-2022) & (K Units)
Table 8. Global Biosimilars of Rituximab Sales Market Share by Region (2017-2022)
Table 9. Global Biosimilars of Rituximab Revenue by Region (2017-2022) & (US$ Million)
Table 10. Global Biosimilars of Rituximab Revenue Market Share by Region (2017-2022)
Table 11. Global Biosimilars of Rituximab Sales Forecast by Region (2023-2028) & (K Units)
Table 12. Global Biosimilars of Rituximab Sales Market Share Forecast by Region (2023-2028)
Table 13. Global Biosimilars of Rituximab Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 14. Global Biosimilars of Rituximab Revenue Market Share Forecast by Region (2023-2028)
Table 15. Top Biosimilars of Rituximab Regions (Countries) Ranking by Market Size (US$ Million) in 2021
Table 16. Biosimilars of Rituximab Market Trends
Table 17. Biosimilars of Rituximab Market Drivers
Table 18. Biosimilars of Rituximab Market Challenges
Table 19. Biosimilars of Rituximab Market Restraints
Table 20. Global Biosimilars of Rituximab Sales by Manufacturers (2017-2022) & (K Units)
Table 21. Global Biosimilars of Rituximab Sales Share by Manufacturers (2017-2022)
Table 22. Global Biosimilars of Rituximab Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 23. Ranking of Global Top Biosimilars of Rituximab Manufacturers by Revenue (US$ Million) in 2021
Table 24. Biosimilars of Rituximab Revenue Share by Manufacturers (2017-2022)
Table 25. Global Biosimilars of Rituximab Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilars of Rituximab as of 2021)
Table 27. Key Manufacturers Biosimilars of Rituximab Average Selling Price (ASP) & (2017-2022) & (US$/Unit)
Table 28. Key Manufacturers Biosimilars of Rituximab Plants/Factories Distribution
Table 29. Key Manufacturers Biosimilars of Rituximab Area Served
Table 30. Date of Key Manufacturers Enter into Biosimilars of Rituximab Market
Table 31. Key Manufacturers Biosimilars of Rituximab Product Type
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Biosimilars of Rituximab Sales (K Units) by Type (2017-2022)
Table 34. Global Biosimilars of Rituximab Sales Share by Type (2017-2022)
Table 35. Global Biosimilars of Rituximab Revenue (US$ Million) Market Share by Type (2017-2022)
Table 36. Global Biosimilars of Rituximab Price (K Units) by Type (2017-2022)
Table 37. Global Biosimilars of Rituximab Sales (K Units) by Type (2023-2028)
Table 38. Global Biosimilars of Rituximab Sales Share by Type (2023-2028)
Table 39. Global Biosimilars of Rituximab Revenue (US$ Million) Market Share by Type (2023-2028)
Table 40. Global Biosimilars of Rituximab Revenue Share by Type (2023-2028)
Table 41. Global Biosimilars of Rituximab Price (K Units) by Type (2023-2028)
Table 42. Global Biosimilars of Rituximab Sales (K Units) by Application (2017-2022)
Table 43. Global Biosimilars of Rituximab Sales Share by Application (2017-2022)
Table 44. Global Biosimilars of Rituximab Revenue (US$ Million) Market Share by Application (2017-2022)
Table 45. Global Biosimilars of Rituximab Price (K Units) by Application (2017-2022)
Table 46. Global Biosimilars of Rituximab Sales (K Units) by Application (2023-2028)
Table 47. Global Biosimilars of Rituximab Sales Share by Application (2023-2028)
Table 48. Global Biosimilars of Rituximab Revenue (US$ Million) Market Share by Application (2023-2028)
Table 49. Global Biosimilars of Rituximab Revenue Share by Application (2023-2028)
Table 50. Global Biosimilars of Rituximab Price (K Units) by Application (2023-2028)
Table 51. North America Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 52. North America Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 53. North America Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 54. North America Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 55. North America Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 56. North America Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 57. North America Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 58. North America Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 59. North America Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 60. North America Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 61. North America Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 62. North America Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 63. North America Biosimilars of Rituximab Sales by Country (2017-2022) & (K Units)
Table 64. North America Biosimilars of Rituximab Sales by Country (2023-2028) & (K Units)
Table 65. North America Biosimilars of Rituximab Revenue by Country (2017-2022) & (US$ Million)
Table 66. North America Biosimilars of Rituximab Revenue by Country (2023-2028) & (US$ Million)
Table 67. Europe Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 68. Europe Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 69. Europe Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 70. Europe Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 71. Europe Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 72. Europe Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 73. Europe Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 74. Europe Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 75. Europe Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 76. Europe Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 77. Europe Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 78. Europe Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 79. Europe Biosimilars of Rituximab Sales by Country (2017-2022) & (K Units)
Table 80. Europe Biosimilars of Rituximab Sales by Country (2023-2028) & (K Units)
Table 81. Europe Biosimilars of Rituximab Revenue by Country (2017-2022) & (US$ Million)
Table 82. Europe Biosimilars of Rituximab Revenue by Country (2023-2028) & (US$ Million)
Table 83. Asia Pacific Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 84. Asia Pacific Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 85. Asia Pacific Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 86. Asia Pacific Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 87. Asia Pacific Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 88. Asia Pacific Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 89. Asia Pacific Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 90. Asia Pacific Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 91. Asia Pacific Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 92. Asia Pacific Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 93. Asia Pacific Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 94. Asia Pacific Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 95. Asia Pacific Biosimilars of Rituximab Sales by Region (2017-2022) & (K Units)
Table 96. Asia Pacific Biosimilars of Rituximab Sales by Region (2023-2028) & (K Units)
Table 97. Asia Pacific Biosimilars of Rituximab Revenue by Region (2017-2022) & (US$ Million)
Table 98. Asia Pacific Biosimilars of Rituximab Revenue by Region (2023-2028) & (US$ Million)
Table 99. Latin America Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 100. Latin America Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 101. Latin America Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 102. Latin America Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 103. Latin America Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 104. Latin America Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 105. Latin America Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 106. Latin America Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 107. Latin America Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 108. Latin America Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 109. Latin America Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 110. Latin America Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 111. Latin America Biosimilars of Rituximab Sales by Country (2017-2022) & (K Units)
Table 112. Latin America Biosimilars of Rituximab Sales by Country (2023-2028) & (K Units)
Table 113. Latin America Biosimilars of Rituximab Revenue by Country (2017-2022) & (US$ Million)
Table 114. Latin America Biosimilars of Rituximab Revenue by Country (2023-2028) & (US$ Million)
Table 115. Middle East and Africa Biosimilars of Rituximab Sales by Company (2017-2022) & (K Units)
Table 116. Middle East and Africa Biosimilars of Rituximab Sales Market Share by Company (2017-2022)
Table 117. Middle East and Africa Biosimilars of Rituximab Revenue by Company (2017-2022) & (US$ Million)
Table 118. Middle East and Africa Biosimilars of Rituximab Revenue Market Share by Company (2017-2022)
Table 119. Middle East and Africa Biosimilars of Rituximab Sales by Type (2017-2022) & (K Units)
Table 120. Middle East and Africa Biosimilars of Rituximab Sales by Type (2023-2028) & (K Units)
Table 121. Middle East and Africa Biosimilars of Rituximab Revenue by Type (2017-2022) & (US$ Million)
Table 122. Middle East and Africa Biosimilars of Rituximab Revenue by Type (2023-2028) & (US$ Million)
Table 123. Middle East and Africa Biosimilars of Rituximab Sales by Application (2017-2022) & (K Units)
Table 124. Middle East and Africa Biosimilars of Rituximab Sales by Application (2023-2028) & (K Units)
Table 125. Middle East and Africa Biosimilars of Rituximab Revenue by Application (2017-2022) & (US$ Million)
Table 126. Middle East and Africa Biosimilars of Rituximab Revenue by Application (2023-2028) & (US$ Million)
Table 127. Middle East and Africa Biosimilars of Rituximab Sales by Country (2017-2022) & (K Units)
Table 128. Middle East and Africa Biosimilars of Rituximab Sales by Country (2023-2028) & (K Units)
Table 129. Middle East and Africa Biosimilars of Rituximab Revenue by Country (2017-2022) & (US$ Million)
Table 130. Middle East and Africa Biosimilars of Rituximab Revenue by Country (2023-2028) & (US$ Million)
Table 131. Amgen Corporation Information
Table 132. Amgen Description and Overview
Table 133. Amgen Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 134. Amgen Biosimilars of Rituximab Product and Services
Table 135. Amgen Biosimilars of Rituximab SWOT Analysis
Table 136. Amgen Recent Developments
Table 137. AryoGen Pharmed Corporation Information
Table 138. AryoGen Pharmed Description and Overview
Table 139. AryoGen Pharmed Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 140. AryoGen Pharmed Biosimilars of Rituximab Product and Services
Table 141. AryoGen Pharmed Biosimilars of Rituximab SWOT Analysis
Table 142. AryoGen Pharmed Recent Developments
Table 143. Biocad Corporation Information
Table 144. Biocad Description and Overview
Table 145. Biocad Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 146. Biocad Biosimilars of Rituximab Product and Services
Table 147. Biocad Biosimilars of Rituximab SWOT Analysis
Table 148. Biocad Recent Developments
Table 149. Cadila Pharmaceuticals Corporation Information
Table 150. Cadila Pharmaceuticals Description and Overview
Table 151. Cadila Pharmaceuticals Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 152. Cadila Pharmaceuticals Biosimilars of Rituximab Product and Services
Table 153. Cadila Pharmaceuticals Biosimilars of Rituximab SWOT Analysis
Table 154. Cadila Pharmaceuticals Recent Developments
Table 155. Celltrion Corporation Information
Table 156. Celltrion Description and Overview
Table 157. Celltrion Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 158. Celltrion Biosimilars of Rituximab Product and Services
Table 159. Celltrion Biosimilars of Rituximab SWOT Analysis
Table 160. Celltrion Recent Developments
Table 161. Dr Reddy's Laboratories Corporation Information
Table 162. Dr Reddy's Laboratories Description and Overview
Table 163. Dr Reddy's Laboratories Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 164. Dr Reddy's Laboratories Biosimilars of Rituximab Product and Services
Table 165. Dr Reddy's Laboratories Biosimilars of Rituximab SWOT Analysis
Table 166. Dr Reddy's Laboratories Recent Developments
Table 167. Teva Corporation Information
Table 168. Teva Description and Overview
Table 169. Teva Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 170. Teva Biosimilars of Rituximab Product and Services
Table 171. Teva Biosimilars of Rituximab SWOT Analysis
Table 172. Teva Recent Developments
Table 173. Hetero Group Corporation Information
Table 174. Hetero Group Description and Overview
Table 175. Hetero Group Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Table 176. Hetero Group Biosimilars of Rituximab Product and Services
Table 177. Hetero Group Biosimilars of Rituximab SWOT Analysis
Table 178. Hetero Group Recent Developments
Table 179. Innovent Biologics Corporation Information
Table 180. Innovent Biologics Description and Overview
Table 181. Innovent Biologics Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2017-2022)
Tabl
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs